- Home
- IBTA vs NRIX Comparison
IBTA vs NRIX Comparison
Compare IBTA & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBTA
- NRIX
- Stock Information
- Founded
- IBTA 2011
- NRIX 2009
- Country
- IBTA United States
- NRIX United States
- Employees
- IBTA N/A
- NRIX N/A
- Industry
- IBTA
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- IBTA
- NRIX Health Care
- Exchange
- IBTA Nasdaq
- NRIX Nasdaq
- Market Cap
- IBTA 926.1M
- NRIX 750.4M
- IPO Year
- IBTA 2024
- NRIX 2020
- Fundamental
- Price
- IBTA $28.97
- NRIX $12.64
- Analyst Decision
- IBTA Hold
- NRIX Strong Buy
- Analyst Count
- IBTA 9
- NRIX 14
- Target Price
- IBTA $38.75
- NRIX $26.29
- AVG Volume (30 Days)
- IBTA 275.6K
- NRIX 1.9M
- Earning Date
- IBTA 11-12-2025
- NRIX 10-09-2025
- Dividend Yield
- IBTA N/A
- NRIX N/A
- EPS Growth
- IBTA 2512.20
- NRIX N/A
- EPS
- IBTA 2.84
- NRIX N/A
- Revenue
- IBTA $367,604,000.00
- NRIX $83,687,000.00
- Revenue This Year
- IBTA N/A
- NRIX $58.48
- Revenue Next Year
- IBTA $0.58
- NRIX N/A
- P/E Ratio
- IBTA $10.17
- NRIX N/A
- Revenue Growth
- IBTA 3.49
- NRIX 48.32
- 52 Week Low
- IBTA $22.50
- NRIX $8.18
- 52 Week High
- IBTA $79.80
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- IBTA 36.09
- NRIX 65.34
- Support Level
- IBTA $32.06
- NRIX $11.98
- Resistance Level
- IBTA $35.23
- NRIX $13.03
- Average True Range (ATR)
- IBTA 1.23
- NRIX 0.82
- MACD
- IBTA -0.60
- NRIX 0.13
- Stochastic Oscillator
- IBTA 2.14
- NRIX 84.74
About IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.